

## UTILIZATION MANAGEMENT MEDICAL POLICY

**POLICY:** Pompe Disease – Enzyme Replacement Therapy – Nexviazyme Utilization Management Medical Policy

- Nexviazyme® (avalglucosidase alfa-ngpt intravenous infusion – Genzyme)

**REVIEW DATE:** 05/06/2026

---

### OVERVIEW

Nexviazyme, a hydrolytic lysosomal glycogen-specific recombinant human  $\alpha$ -glucosidase enzyme, is indicated for **late-onset Pompe disease** (lysosomal acid  $\alpha$ -glucosidase deficiency) in patients  $\geq 1$  year of age.<sup>1</sup>

### Disease Overview

Pompe disease (glycogen storage disease type II, or acid maltase deficiency), is a rare lysosomal storage disorder characterized by a deficiency in acid  $\alpha$ -glucosidase activity leading to the accumulation of glycogen, particularly in muscle.<sup>2</sup> In general, the condition is defined by the age of onset, organ involvement, severity and rate of progression. Late-onset Pompe disease has a more variable clinical course and can manifest any time after 12 months of age. Patients typically present with progressive muscle weakness which can progress to respiratory insufficiency. The diagnosis of Pompe disease is established a deficiency of acid  $\alpha$ -glucosidase activity or by identification of biallelic pathogenic variants by genetic testing. Enzyme replacement therapy has an important role in the management of Pompe disease.

### POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Nexviazyme. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Nexviazyme as well as the monitoring required for adverse events and long-term efficacy, approval requires Nexviazyme to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Nexviazyme is recommended in those who meet the following criteria:

#### FDA-Approved Indication

- 
- 1. Acid Alpha-Glucosidase Deficiency (Pompe Disease).** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):
    - A) Patient is  $\geq 1$  year of age; AND
    - B) Patient has late-onset acid alpha-glucosidase deficiency (late-onset Pompe disease); AND
    - C) The diagnosis is established by ONE of the following (i or ii):
-

- i. Patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue; OR
  - ii. Patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic acid alpha-glucosidase (GAA) gene variants; AND
- D)** The medication is prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

**Dosing.** Approve ONE of the following dosing regimens (A or B):

- A)** Patient  $\geq$  30 kg: Dose is 20 mg/kg administered by intravenous infusion once every 2 weeks; OR
- B)** Patient  $<$  30 kg: Dose is 40 mg/kg administered by intravenous infusion once every 2 weeks.

---

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Nexviazyme is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Nexviazyme® intravenous infusion [prescribing information]. Cambridge, MA: Genzyme; September 2023.
2. Sperry E, Leslie N, Berry L, et al. Pompe Disease. 2007 Aug 31 [Updated 2025 Aug 21]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1261/>. Accessed on May 4, 2026.

### HISTORY

| Type of Revision      | Summary of Changes                                                                                                                                                                                                                                                                     | Review Date |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Early Annual Revision | <b>Acid Alpha-Glucosidase Deficiency (Pompe Disease):</b> Confirmation of a genetic mutation in the acid alpha-glucosidase gene was rephrased to more specifically state, “genetic test demonstrating biallelic pathogenic or likely pathogenic acid alpha-glucosidase gene variants”. | 05/08/2024  |
| Annual Revision       | No criteria changes.                                                                                                                                                                                                                                                                   | 05/07/2025  |
| Annual Revision       | No criteria changes.                                                                                                                                                                                                                                                                   | 05/06/2026  |